DLDoris Laos-Anchante

Doris Laos-Anchante

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Doris Laos-Anchante has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CYP2C9 Pharmacogenetic Variants and Adverse Drug Reactions to Antiseizure Medications: An Exploratory Analysis in the Venezuelan Andes

    by Alexis Morales-Ortiz, Luis Abel Quiñones, Sol Betzabeth Rondón-Simancas, Gustavo Paredes, Andrea Avendaño, Zaida Gonzalez, Haydee Chávez, Juan J. Palomino-Jhong, María R. Bendezú, Jorge A. García, et al.

    Epilepsy is a chronic neurological disorder with a high global prevalence. In Venezuela, the limited availability of epidemiological and pharmacogenetic data represents an important public health challenge. Antiseizure medications (ASMs) are frequently associated with adverse drug reactions (ADRs), which may be influenced by genetic variability in drug-metabolising enzymes. This study evaluated the association between the CYP2C9*2 and CYP2C9*3 variants and the occurrence of ADRs in patients receiving anticonvulsant treatment in the Venezuelan Andes. An observational, analytical, cross-sectional study was conducted in 72 patients. Genomic DNA was extracted from venous blood, and CYP2C9 genotypes were determined by real-time PCR using TaqMan® probes. The frequencies of the CYP2C9*2 and CYP2C9*3 alleles were 0.15 and 0.06, respectively. The metaboliser phenotype was significantly associated with the presence of ADRs. The risk of ADRs was elevated in the intermediate/poor metaboliser group (IM/PM: OR = 17.45; 95%CI: 5.09–76.56; p < 0.001) and in patients on polypharmacy (OR = 15.03; 95%CI: 2.73–157.37; p = 0.001), although this latter estimate showed marked imprecision due to the width of its interval. Consistent with this, the ADR rate was higher in PM (100%; 3/3) and IM (84.2%; 16/19) than in normal group (20.9%; 9/43). In the monotherapy subgroup, the type of ASM showed no association with the occurrence of ADR (p = 0.741). Among normal metabolisers receiving polytherapy, regimens containing valproic acid were associated with the highest proportion of ADRs, with dual therapy including lamotrigine accounting for 28.57%. Although the overall analysis indicated differences in ADR occurrence according to polytherapy regimen (p = 0.043), the limited sample size restricts the strength of these findings. These results suggest that CYP2C9*2 and CYP2C9*3 variants may contribute to variability in the safety of anticonvulsant treatment among patients from the Venezuelan Andes by influencing CYP2C9 metaboliser phenotypes, and consequently, drug pharmacokinetics. Further studies in larger and more representative Venezuelan populations are warranted to validate these findings.


  • Open Access

    CYP2C9 Pharmacogenetic Variants and Adverse Drug Reactions to Antiseizure Medications: An Exploratory Analysis in the Venezuelan Andes

    by Sol Betzabeth Rondón-Simancas, Gustavo Paredes, Andrea Avendaño, Alexis Morales-Ortiz, Zaida Gonzalez B, Luis Abel Quiñones, Juan J. Palomino-Jhong, María R. Bendezú, Jorge A. García, Haydee Chávez, et al.

    Background/Objectives: Epilepsy is a chronic neurological disorder affecting more than 50 million people worldwide. All antiseizure medications may cause adverse drug reac-tions (ADRs), including neurological, cognitive, mood-related, and systemic manifesta-tions. In Venezuela, epilepsy represents a public health challenge due to the lack of epi-demiological and pharmacogenetic data. This study evaluated the association between the CYP2C9*2 and CYP2C9*3 variants and the incidence of adverse drug reactions in patients receiving antiseizure therapy in the Venezuelan Andean region. Methods: An observa-tional, descriptive, and cross-sectional study in 72 patients, was conducted. Genomic DNA was extracted from venous blood samples, and genotypes were determined by re-al-time polymerase chain reaction (PCR) using TaqMan® probes for allelic discrimination. Results: The observed allele frequencies were 0.15 for CYP2C9*2 and 0.06 for CYP2C9*3. Patients with intermediate and poor metabolizer phenotypes exhibited a significantly higher risk of developing ADRs compared with normal metabolizers (OR = 16.33; 95% CI: 4.30–62.01; p < 0.001). Likewise, polytherapy markedly increased the risk of ADRs com-pared with monotherapy (OR = 25.71; 95% CI: 2.60–254.03; p = 0.005). Conclusion: The CYP2C9*2 and CYP2C9*3 variants may influence the safety of antisei-zure therapy in patients from the Venezuelan Andes by determining intermediate and poor metabolizer phenotypes and thereby affecting the pharmacokinetics of these medica-tions, as previously reported in international studies.

  • Open Access

    Physicochemical, biochemical characterization and antioxidant activity of artisanal honey from coastal and Andean regions of Peru

    by Felipe Surco-Laos, Jorge A. García, María R. Bendezú, Haydee Chávez, Juan J. Palomino-Jhong, Doris Laos-Anchante, Elizabeth J. Melgar-Merino, Pompeyo A. Cuba-Garcia, Paulina Eliades Yarasca-Carlos, Angel T. Alvarado

    Context: Honey contains phenolic constituents and minerals that contribute to measurable in vitro antioxidant capacity, which may vary with botanical and geographic origin. Aims: To evaluate physicochemical parameters, total polyphenol content (TPC), total flavonoid content (TFC), mineral composition, and in vitro antioxidant capacity in artisanal honey samples collected from coastal and Andean regions of Peru. Methods: Eleven coded honey samples were analyzed in triplicate (analytical replicates). TPC was determined by the Folin–Ciocalteu assay and TFC by an AlCl₃-based colorimetric assay. Antioxidant capacity was assessed using DPPH and FRAP assays. Minerals were quantified by flame atomic absorption spectrophotometry after incineration and acid digestion. Results: TPC and TFC differed across samples, and DPPH/FRAP responses varied by sample. A significant correlation was observed between TPC and TFC, and between DPPH and FRAP; however, no significant monotonic association between antioxidant capacity and TPC/TFC was detected in this dataset. Conclusions: Peruvian artisanal honey samples showed acceptable physicochemical indices and variable in vitro antioxidant capacity. Botanical authentication and compound-level profiling are required to strengthen floral-origin conclusions and to clarify the determinants of antioxidant capacity.

  • Open Access

    Association Between CYP2C9 and CYP2C19 Genetic Polymorphisms and Antiseizure Medication-Induced Adverse Reactions Among Peruvian Patients with Epilepsy

    by Angel T. Alvarado, Felipe L. Ignacio-Cconchoy, Juan C. Espinoza-Retuerto, Roxana M. Contreras-Macazana, Luis Abel Quiñones, Jorge A. García, María R. Bendezú, Haydee Chávez, Felipe Surco-Laos, Doris Laos-Anchante, et al.

    Background/Objectives: Epilepsy is characterized by recurrent, unprovoked, self-limiting seizures of genetic, acquired, or unknown origin. It affects more than 50 million people worldwide. The prevalence in Peru is 11.9–32.1 per 1000 people. Our objective was to describe the association between CYP2C9 and CYP2C19 genetic polymorphisms and adverse reactions induced by antiseizure medications among Peruvian patients with epilepsy. Methods: A descriptive observational study was conducted on Peruvian patients with epilepsy. Non-probability, non-randomized, purposive sampling was carried out through consecutive inclusion. Genomic DNA was obtained from venous blood samples. Genotypes were determined by real-time PCR using specific TaqMan probes to identify the alleles of interest. Results: In total, 89 Peruvian patients with epilepsy were recruited at the Alberto Sabogal Sologuren National Hospital-ESSALUD: 45 were male (23.6 ± 10.0 years) and 44 were female (24.0 ± 12.4 years). The observed frequencies for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, and CYP2C19*17 were 0.034 (T allele), 0.034 (C allele), 0.14 (A allele), 0.00 (A allele), and 0.03 (T allele), respectively. Patients with intermediate and poor metabolic phenotypes of CYP2C9 and CYP2C19 had a significantly higher risk of adverse drug reactions (ADRs) (OR = 3.75; 95%CI: 1.32–10.69; p = 0.013), compared with normal metabolizers. Polytherapy was a predictor increasing the likelihood of ADRs (OR = 4.33; 95% CI: 1.46–12.80; p = 0.008). Conclusions: In this cohort of Peruvian patients with epilepsy, the reduced-function alleles CYP2C9*2, CYP2C9*3, and CYP2C19*2, associated with decreased metabolic activity, were significantly linked to an increased risk of adverse drug reactions induced by antiseizure medications. Polytherapy further heightened this risk. Collectively, these findings highlight the clinical relevance of CYP2C9 and CYP2C19 genotyping to enhance the safety of antiseizure pharmacotherapy in Latin American settings, where pharmacogenomic evidence remains limited.


  • Open Access

    Pharmacogenes associated with adverse reactions induced by second-generation antipsychotic drugs: A systematic review

    by Erick A. Alvarado-Vera, César André Alvarado-Vera, Angel T. Alvarado, María Saravia Bartra, Jorge A. García, María R. Bendezú, Juan J. Palomino-Jhong, Haydee Chávez, Doris Laos-Anchante, Elizabeth J. Melgar-Merino, et al.

    Pharmacogenes are specific genes that determine how an individual will respond to medication. Some of these genes have been linked to adverse reactions caused by second-generation antipsychotics. A literature search was conducted using relevant terms across the PubMed, CTG Studies, and Scopus databases. The included articles examined pharmacogenes associated with adverse reactions induced by second-generation antipsychotics. The articles were published between 2015 and 2025. A total of 12 observational studies were included. The review protocol is registered in PROSPERO (CRD420251035803). The studies demonstrated an association of CYP1A2 with adverse reactions induced by aripiprazole ( p < 0.035), clozapine ( p = 0.009, p = 0.042, and p = 0.046), and olanzapine ( p < 0.05). CYP2C19 was associated with clozapine-induced metabolic syndrome ( p < 0.01). CYP3A4 was associated with clozapine-induced hyperglycemia (χ² = 0.1), and CYP3A5 was associated with quetiapine ( p < 0.007). CYP2D6 was linked to adverse reactions induced by clozapine ( p = 0.039), olanzapine ( p = 0.047), risperidone ( p = 0.021 and p = 0.02), and quetiapine ( p = 0.003). This review shows that certain allelic variants of pharmacogenes are associated with adverse reactions to second-generation antipsychotics. This finding applies to patients with impaired metabolism. We recommend conducting longitudinal multicenter studies before promoting allelic variants of pharmacogenes as predictive biomarkers.

  • Open Access

    CYP1A1 and GSTM1 genes associated with the risk of developing colorectal cancer: a case-control study in the Lima region of Peru

    by Angel T. Tito Alvarado, María Saravia-Bartra, Robert Malpartida-Palomino, Cynthya Carolin Cárdenas-Guerrero, Jorge A. García, María R. Bendezú, Haydee Chávez, Doris Laos-Anchante, Juan J. Palomino-Jhong, Aura Molina-Cabrera, et al.

    The presence of CYP1A1 allelic variants and deletion of the glutathione S-transferase GSTM1 gene, and their imbalance, have been suggested as risk factors for inducing colorectal cancer (CRCa). The objective was to identify CYP1A1 and GSTM1 and evaluate the association with the risk of developing colorectal cancer in a sample of cases and controls from Lima, Peru. This was a case-control study of CYP1A1 and GSTM1 genes in 50 samples from patients diagnosed with colorectal cancer and 50 samples from controls without cancer, using the PCR-based restriction fragment length polymorphism method. A significant risk of developing CRCa was found in the following groups: GSTM1*0 carriers with no history of smoking or family history of cancer (OR = 3.56, 95% CI 1.43–8.88, p = 0.0060); GSTM1*0 with family history of cancer without smoking (OR = 2.81, 95% CI 0.35–22.49, p = 0.3280); GSTM1*0 exacerbated by smoking (OR = 1.41, 95% CI 0.11–17.11, p = 0.7880); CYP1A1*2A/*2A carriers with family history and smoking (OR = 1.50, 95% CI 0.13–16.54, p = 0.7410). An association of wild genotypes exacerbated by non-genetic factors with risk of developing CRCa was also found: CYP1A1*1A/*1A with family history of cancer but no history of smoking (OR = 2.94, 95% CI 0.11–35.80, p = 0.6380); GSTM1 (+) with history of smoking but no family history of cancer (OR = 5.63, 95% CI 0.46–68.46, p = 0.1750); GSTM1 (+) associated with family history and smoking (OR = 9.86, 95% CI 1.77–54.89, p = 0.0090). According to univariate statistical analysis, carriers of CYP1A1*2A and GSTM1*0 without association with family history of cancer and smoking would not be related to the risk of CRCa. An association was established between GSTM1*0 and CYPA1*2A/*2A with colorectal cancer exacerbated by family history and smoking. The risk is higher with wild-type genotypes of CYP1A1*1A/*1A and GSTM1 (+) induced by family history and smoking, respectively.


  • Open Access

    CYP3A4*20, CYP3A4*22, CYP2C8*3 and SLCO1B1 as genetic biomarkers to predict peripheral neuropathy induced by paclitaxel and docetaxel: A systematic review

    by Angel T. Alvarado, Mario Bolarte-Arteaga, Mario Pineda-Pérez, César Li-Amenero, Haydee Chávez, María R. Bendezú, Jorge A. García, Juan J. Palomino-Jhong, Carmela Ferreyra-Paredes, Elizabeth J. Melgar-Merino, et al.

    Context: Cancer is a global health problem with a growing incidence year after year, and it is projected that by 2040, there will be more than 2.4 million cases in Latin America and the Caribbean, being the second cause of death in these countries. The variability of serum levels, efficacy and safety of paclitaxel and docetaxel have been associated with allelic variants of transporter and metabolizing proteins. Aims: To review the most updated and available scientific evidence on allelic variants of CYP3A4*20, CYP3A4*22, CYP2C8*3, and SLCO1B1 as genetic biomarkers to predict peripheral neuropathy induced by paclitaxel and docetaxel. Methods: PRISMA was used, and a standardized search was followed in Medline/PubMed and Google Scholar with the terms: CYP3A4, CYP2C8, SLCO1B1, genetic biomarker of neuropathy and neuropathy due to paclitaxel and docetaxel. Data extraction was performed using Excel, and relevant information on allelic variants was collected as genetic biomarkers to predict peripheral neuropathy induced by paclitaxel and docetaxel. Results: Eight studies indicate an association between the allelic variants of the study with peripheral neuropathy: CYP2C8*3 (HR: 1.93; 95% CI: 1.05-3.55; p=0.006), CYP3A4*22 (p=0.043), CYP3A4*20, CYP3A4*8 and CYP3A4*27 (p=5.9 × 10-5), CYP2C8 and CYP3A4 (p=1.8 × 10-6), SLCO1B1 (HR: 0.67; 95% CI: 0.46-0.97; p=0.02), SLCO1B3 (OR: 9.44), CYP3A4 (OR: 2.259; 95% CI: 1.033-4.941; p=0.038), CYP3A4*22 (RR: 6.92; 95% CI: 0.47-99.8; p=0.0766) and CYP2C8*3/*4 (RR: 1.28; 95% CI: 0.96-1.67; p=0.0898). No pharmacogenetic studies were found in cancer patients in Peruvian populations. Conclusions: Based on the review of the published scientific evidence, it is concluded that the allelic variants CYP3A4*22, CYP3A4*20 and CYP2C8*3 are associated with a modest risk of peripheral neuropathy induced by paclitaxel and docetaxel, while SLCO1B1 has less evidence.


  • Open Access

    Prevalence of GSTM1*0 and CYP1A1*2A (rs4646903) variants in the central Peruvian coastal population: Pilot Study of predictive genetic biomarkers for 4P medicine

    by Angel T. Alvarado, Alberto Salazar-Granara, Nelson Varela, Luis Abel Quiñones, César Li-Amenero, María R. Bendezú, Jorge A. García, Felipe Surco-Laos, Haydee Chávez, Juan J. Palomino-Jhong, et al.

    The CYP1A1 isoenzyme is responsible for the biotransformation of procarcinogens, such as Benzo(a)pyrene, into reactive metabolites. Meanwhile, GSTM1 facilitates the detoxification of these metabolites by conjugating them with glutathione. The presence of the CYP1A1*2A genetic variant intensifies the production of these reactive metabolites, and the deletion of the GSTM1 gene (GSTM1*0) impairs their detoxification. This enzymatic imbalance leads to the formation of DNA adducts, which are known to contribute to cancer and other diseases. Given the importance of studying these genes within the framework of 4P medicine (predictive, preventive, personalized, and participatory), the primary objective of this study was to investigate the prevalence of GSTM1*0 and CYP1A1*2A in the central Peruvian coastal Population as genetic biomarkers. The study included 131 individual residents of the Peruvian towns of Ica and Lima. The results showed a frequency of 0.47 for GSTM1*0 and an allele frequency of 0.68 for CYP1A1*2A. The genotype frequencies of CYP1A1*2A were 6% *1A/*1A, 53% *1A/*2A, and 41% *2A/*2A. Notably, the population sample is not in the Hardy-Weinberg equilibrium (χ2 = 5.324) for CYP1A1. The reported frequencies of GSTM1*0 and CYP1A1*2A in this study differ from those previously documented for other Latin American and tricontinental populations, potentially reflecting the unique natural evolution and genetic admixture of the Peruvian population. The high prevalence of GSTM1*0 and CYP1A1*2A identified in populations from Ica and Lima suggests a potentially elevated risk of exposure to procarcinogens such as polycyclic aromatic hydrocarbons (PAHs). This finding underscores the need for further research on a larger scale to validate and expand upon these results. Graphical abstract:


  • Open Access

    Anti-inflammatory effect of the total flavonoid content of the hydroalcoholic extract of the leaves of Senna alata (L.) Roxb. in an experimental model of acute inflammation

    by Haydee Chávez, Angel T. Alvarado, Nesquen T Asayco-Yataco, Mario Pineda Pérez, Jorge A. García, María R. Bendezú, Felipe Surco-Laos, Juan J. Palomino-Jhong, Doris Laos-Anchante, Elizabeth J. Melgar-Merino, et al.

    Context: Acute inflammation due to persistent stimulation of noxes evolves into chronic inflammation that contributes to the pathogenesis of asthma, arthritis, atherosclerosis, diabetes, aging, and cancer; therefore, it is justified to study plants with anti-inflammatory activity and fewer adverse effects. Aims: To evaluate the potential anti-inflammatory effect of the total flavonoid content of the hydroalcoholic extract of the leaves of Senna alata (L.) Roxb (HELSA) in an experimental model of acute inflammation induced by carrageenan in rats. Methods: The total flavonoid content (TFC) was determined by spectrophotometry at 510 nm, total polyphenolic content (TPC) by the Folin-Ciocalteu method, and antioxidant activity by two in vitro methods. The oral median lethal dose (LD50) was determined by the logarithmic method, and acute inflammation was induced by 1% carrageenan in rats. Results: The TFC was 1.63 ± 0.02 mg QE/100 mg and TPC was 22.90 ± 0.05 mg GAE/100 mg. Antioxidant capacity: DPPH IC50 2.89 ± 0.04 µg/µL; ABTS 11.67 ± 0.03 mM TEAC/100 mg dry extract. Correlation relationship TFC/DPPH (r = -0.9941; R2 = 0.9884), TFC/ABTS (r = 0.9971; R2 = 0.9944), TPC/DPPH (r = 0.5694; R2 = 0.3243) and TPC/ABTS (r = -0.5960; R2 = 0.3553). The LD50 was 9602 mg/kg. A significant decrease in rat paw edema (p<0.05) was evident from the first hour, in contrast to the negative control. The highest percentage of anti-inflammatory inhibition (75.75%) was at 7 hours with a dose of 500 mg/kg of HELSA, being higher than the effect of ibuprofen (39.40%) and lower than dexamethasone (87.87%). Conclusions: The total flavonoid content and polyphenols of the hydroalcoholic extract of the leaves of S. alata exhibit potential anti-inflammatory activity in a model of acute inflammation that should be examined with other experimental models to initiate clinical trials in humans.


  • Open Access

    Biophenolic compounds and metal ions associated with the antioxidant and antibacterial activity of the ethanolic extract of Heliotropium arborescens L. leaves from the Andean region of Ayacucho-Peru

    by Angel T. Alvarado, Haydee Chávez, Jorge A. García, María R. Bendezú, Felipe Surco-Laos, Aura Molina-Cabrera, Doris Laos-Anchante, Nelly Vega-Ramos, Juan J. Palomino-Jhong, Paulina Eliades Yarasca-Carlos, et al.

    Heliotropium arborescens (Galán de Mera et al. 2022) is a herbaceous plant that contains various biophenolic compounds that exhibit antibacterial property and antioxidant activity that could prevent diseases caused by free radicals. The objective was to study the biophenolic compounds and metal ions associated with the in vitro antioxidant and antibacterial activity of the ethanolic extract of Heliotropium arborescens L. leaves from the Andean region of Ayacucho-Peru. The total polyphenolic content (TPC) was determined by the Folin-Ciocalteu method; Total flavonoid content (TFC) was determined by spectrophotometry at 510 nm, TFC was expressed in mg quercetin/g sample (mg QE/g). Antioxidant activity by three in vitro methods; determination of metals by flame atomic absorption spectrophotometry (FAAS) and antibacterial activity by agar diffusion method. The values ​​obtained from the TPC were 306.80±0.05 mg GAE/g, TFC 111.53±0.25 mg QE/g. Antioxidant activity: DPPH IC50 37.55±0.04 µL and 65.64±0.10 µL, at 0.47 and 0.93 mg/mL extract, respectively; ABTS 0.20±0.01 mM TEAC/g (0.41 mg/mL extract) and 0.47±0.01 (0.82 mg/mL extract); FRAP 0.24±0.01 mM TEAC/g (0.94 mg/mL extract) and 0.46±0.02 mM TEAC/g (1.88 mg/mL extract). Correlation relationship TFC/DPPH (r=0.9994; R2 0.9989), TFC/ABTS (r = 0.9572; R2 0.9998) and TFC/FRAP (r = 09933; R2 0.9868). Calcium 1.22±0.04, copper 0.77±0.05, magnesium 851.7±3.06 and zinc 20.63±1.19 mg/100 g were found in all cases. Antibacterial activity on Bacillus subtilis (ATCC 6633) and Staphylococcus aureus (ATCC 25923) with a minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) > 400 μg/mL. It is concluded that the total biophenolic components and metals of the ethanolic extract of the leaves of H. arborescens L. show potential antioxidant activity, and moderate antibacterial activity against Bacillus subtilis and Staphylococcus aureus. Graphical abstract: